Live Breaking News & Updates on Bridgebio Pharma Inc

Stay updated with breaking news from Bridgebio pharma inc. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Sectoral Asset Management Inc. Sells 167,240 Shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO)

Sectoral Asset Management Inc. cut its holdings in shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO – Free Report) by 92.8% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 12,955 shares of the company’s stock after selling 167,240 shares during the quarter. Sectoral […] ....

Randalw-scott , Bio-pharma , Jpmorgan-chase-co , Boone-capital-management , Bio-pharma-inc , Manufacturers-life-insurance-company , Nasdaq , Campbell-co-investment-adviser , Securities-exchange-commission , Sectoral-asset-management-inc , Cantor-fitzgerald

Sectoral Asset Management Inc. Sells 167,240 Shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO)

Sectoral Asset Management Inc. cut its holdings in shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO – Free Report) by 92.8% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 12,955 shares of the company’s stock after selling 167,240 shares during the quarter. Sectoral […] ....

Randalw-scott , Bio-pharma , Sectoral-asset-management-inc , Securities-exchange-commission , Primecap-management-co , Bridgebio-pharma-inc , Cantor-fitzgerald , Bio-pharma-inc , Boone-capital-management , Jpmorgan-chase-co , Campbell-co-investment-adviser

BridgeBio to Host Call on Month 12 and 18 Phase 2 Cohort 5 Results of Oral Infigratinib in Achondroplasia on June 4, 2024

PALO ALTO, Calif., June 03, 2024 BridgeBio Pharma, Inc. , a commercial-stage biopharmaceutical company focused on genetic diseases, today announced that members of its management team, along. ....

Melbourne , Victoria , Australia , Ravi-savarirayan , Vikram-bali , Nasdaq , Linkedin , Twitter , Bridgebio-pharma-inc , Bio-pharma-inc , Murdoch-children-research-institute , Bio-pharma

HC Wainwright Reiterates Buy Rating for BridgeBio Pharma (NASDAQ:BBIO)

BridgeBio Pharma (NASDAQ:BBIO – Get Free Report)‘s stock had its “buy” rating restated by equities researchers at HC Wainwright in a research report issued to clients and investors on Thursday, Benzinga reports. They presently have a $43.00 price target on the stock. HC Wainwright’s target price suggests a potential upside of 53.52% from the company’s […] ....

Bridgebio-pharma , Raymond-james , Bio-pharma , Investment-advisors-inc , Bridgebio-pharma-inc , Healthcare-of-ontario-pension-plan-trust-fund , Citigroup , Entrypoint-capital , Assetmark-inc , Jpmorgan-chase-co , Get-free-report , Point-capital

BridgeBio Pharma (NASDAQ:BBIO) Earns "Overweight" Rating from Cantor Fitzgerald

Cantor Fitzgerald restated their overweight rating on shares of BridgeBio Pharma (NASDAQ:BBIO – Free Report) in a report issued on Tuesday morning, Benzinga reports. They currently have a $70.00 price target on the stock. Other equities analysts have also recently issued research reports about the stock. JPMorgan Chase & Co. raised their price target on […] ....

United-states , Arizona , American , Bridgebio-pharma , Raymond-james , Bio-pharma , Kokusai-asset-management-co , Cantor-fitzgerald , Bridgebio-pharma-inc , Mitsubishi-ufj , Jpmorgan-chase-co , American-international-group-inc